Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dare Bioscience (DARE) EBITDA (2016 - 2025)

Dare Bioscience (DARE) has disclosed EBITDA for 8 consecutive years, with -$3.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 24.01% year-over-year to -$3.6 million, compared with a TTM value of -$17.5 million through Sep 2025, down 393.17%, and an annual FY2024 reading of -$4.1 million, up 86.34% over the prior year.
  • EBITDA was -$3.6 million for Q3 2025 at Dare Bioscience, up from -$4.0 million in the prior quarter.
  • Across five years, EBITDA topped out at $12.9 million in Q2 2024 and bottomed at -$15.8 million in Q4 2022.
  • Average EBITDA over 5 years is -$6.1 million, with a median of -$7.3 million recorded in 2022.
  • The sharpest move saw EBITDA tumbled 3261.62% in 2023, then skyrocketed 246.99% in 2024.
  • Year by year, EBITDA stood at -$9.5 million in 2021, then tumbled by 65.47% to -$15.8 million in 2022, then skyrocketed by 68.29% to -$5.0 million in 2023, then decreased by 11.47% to -$5.6 million in 2024, then skyrocketed by 36.19% to -$3.6 million in 2025.
  • Business Quant data shows EBITDA for DARE at -$3.6 million in Q3 2025, -$4.0 million in Q2 2025, and -$4.4 million in Q1 2025.